WO2012104869A1 - Treatment for lipodystrophy - Google Patents

Treatment for lipodystrophy Download PDF

Info

Publication number
WO2012104869A1
WO2012104869A1 PCT/IN2012/000069 IN2012000069W WO2012104869A1 WO 2012104869 A1 WO2012104869 A1 WO 2012104869A1 IN 2012000069 W IN2012000069 W IN 2012000069W WO 2012104869 A1 WO2012104869 A1 WO 2012104869A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
treatment
lipodystrophy
formula
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2012/000069
Other languages
French (fr)
Inventor
Dhiraj GAMBHIRE
Rajendrakumar Hariprasad JANI
Bipin Pandey
Kaushik Sata
Himanshu KOTHARI
Pankaj Ramanbhai Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zydus Lifesciences Ltd
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2013551015A priority Critical patent/JP2014504610A/en
Priority to CN2012800067602A priority patent/CN103354757A/en
Priority to SI201230540A priority patent/SI2670486T1/en
Priority to UAA201309497A priority patent/UA110813C2/en
Priority to KR1020137021703A priority patent/KR20130128451A/en
Priority to AU2012212992A priority patent/AU2012212992B2/en
Priority to KR1020157022081A priority patent/KR101633720B1/en
Priority to US13/978,791 priority patent/US10017470B2/en
Priority to MEP-2016-73A priority patent/ME02392B/en
Priority to EA201391108A priority patent/EA025421B1/en
Priority to MYPI2013701165A priority patent/MY191100A/en
Priority to SG2013050430A priority patent/SG191772A1/en
Priority to PH1/2013/501533A priority patent/PH12013501533A1/en
Priority to RS20160295A priority patent/RS54735B1/en
Priority to HRP20160403TT priority patent/HRP20160403T1/en
Priority to NZ612804A priority patent/NZ612804B2/en
Priority to BR112013019352-2A priority patent/BR112013019352A2/en
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to MX2013008012A priority patent/MX350611B/en
Priority to KR1020167007592A priority patent/KR101733414B1/en
Priority to EP12710562.5A priority patent/EP2670486B1/en
Priority to AP2013006988A priority patent/AP3920A/en
Priority to CA2825456A priority patent/CA2825456C/en
Priority to DK12710562.5T priority patent/DK2670486T3/en
Priority to PL12710562T priority patent/PL2670486T3/en
Priority to ES12710562.5T priority patent/ES2569248T3/en
Publication of WO2012104869A1 publication Critical patent/WO2012104869A1/en
Priority to IL22726613A priority patent/IL227266B/en
Anticipated expiration legal-status Critical
Priority to SM201600129T priority patent/SMT201600129B/en
Priority to US15/345,035 priority patent/US9783495B2/en
Priority to US15/992,957 priority patent/US20190100492A1/en
Priority to IL262611A priority patent/IL262611A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Definitions

  • the present invention is related to the development of therapeutic compound for prevention and treatment of lipodystrophy.
  • the invention relates to the development of therapeutic compound for prevention and treatment of lipodystrophy in HIV -infected patients (LDHIV).
  • the present invention further provides a suitable composition useful in the treatment or prevention or alleviation of the symptoms of lipodystrophy in HIV infected patients (LDHIV)
  • Lipodystrophy is a very dreadful disease and has become a major global health problem. It is a disorder of fat metabolism which causes lipohypertrophy, Lipoatrophy and Metabolic abnormalities. Moreover, lipohypertrophy includes the enlargement of dorsocervical fat pad (commonly called "buffalo hump"), expansion of the circumference of the neck by 5-10 cm, hypertrophy occuring in breast, central truncal adiposity resulting from abdominal visceral fat accumulation, symmetric and asymmetric lipomatoses. A rare pattern of lipoaccumulation involves formation of band like lipomatosis tissue symmetrically from the breasts, laterally to the axillae, Suprapubic fat pads (pubic lipomas) and the development of multiple angiolipomas.
  • pubic lipomas Suprapubic fat pads
  • Lipoatrophy includes a temporal wasting and loss of subcutaneous fat from the cheeks (buccal fat pad) which produces an emaciated appearance with prominent nasolabial creases. Further subcutaneous tissue is depleted from the arms, shoulders, thighs, and buttocks (peripheral wasting), with prominence of the superficial veins in these sites.
  • Metabolic abnormalities include augmentation in cholesterol and triglyceride levels and reduced high-density lipoprotein (HDL) cholesterol levels, Insulin resistance, type 2 diabetes mellitus, and lactic academia.
  • HDL high-density lipoprotein
  • Lipodystrophy is very commonly associated with the HIV patients who are being treated anti-retroviral medicines.
  • Such medicines can include HIV-1 protease inhibitors (Pis), Nucleoside reverse transcriptase inhibitors (NRTIs), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Fusion Inhibitors, Entry Inhibitors - CCR5 co-receptor antagonist, HIV integrase strand transfer inhibitors etc. These medicines improve the survival of the patient but also produce lipohypertrophy, Lipoatrophy and other Metabolic abnormalities.
  • HIV-1 protease inhibitors appear to be the strongest link to lipodystrophy in HIV -infected patients LDH1V as it inhibits maturation of sterol response element binding proteins (SREBP), which affect intracellular fatty acid and glucose metabolism and adipocyte differentiation (Mallon et al, J Infect Dis, 2005). Furthermore, the Pis also down-regulate peroxisome proliferator-activated receptor gamma (PPAR ⁇ ), an important nuclear transcription factor that is affected by SREBPs and is necessary for adipocyte differentiation and function and fatty acid metabolism.
  • SREBP sterol response element binding proteins
  • PPAR ⁇ peroxisome proliferator-activated receptor gamma
  • LDHIV length of HIV infection, age, and gender
  • Other factors such as duration of HIV infection, age, and gender, may also contribute to the risk of development of LDHIV.
  • the molecular basis of LDH1V is still remains unknown and no specific therapy is available for LDHIV.
  • nRTls Reverse transcriptase inhibitors like stavudine, didanosine and zidovudine may cause mitochondrial toxicity by inhibiting mitochondrial DNA polymerase-yin fat and other tissues and thus interfering with respiratory chain complexes. The result is impaired fatty acid oxidation and intracellular accumulation of triglycerides and lactate
  • lipodystrophy is also observed in acute HIV infection, lending support to a direct viral role as well.
  • Potential host risk factors include age, sex, and race or ethnicity. Lipodystrophy is more common in older patients; fat accumulation is more common in women and lipoatrophy in men; and non-Hispanic black patients appear to be at lower risk of lipoatrophy.
  • a genetic component is indicated by a recent analysis in AIDS Clinical Trials Group (ACTG) , study 5005s, suggesting either predisposition or protection associated with mitochondrial DNA polymorphisms.
  • Testosterone replacement to physiologic levels reduces visceral adipose tissue (VAT), total fat, and abdominal fat and improves insulin sensitivity and lipid profile in older, non-HI.V-infected men with upper body obesity and low testosterone levels.
  • VAT visceral adipose tissue
  • 88 HIV-infected men with central obesity (waist circumference >100 cm) and low testosterone levels ( ⁇ 400 ng/dL) underwent randomization to testosterone as a transdermal gel at a dose of 10 g daily or placebo for 24 weeks (Bhasin et al, J Clin Endocrinol Metab, 2007).
  • the testosterone group had statistically significant reductions in abdominal fat (-1 .5% vs +4.3%), abdominal subcutaneous adipose tissue (SAT) (- 7.2% vs +8.1 %), trunk fat (-9.9% vs +4.6%), and limb fat (-10.1 % vs +3.1 %); the latter finding is of potential concern in a population predisposed to lipoatrophy. No statistically significant difference in change in VAT (+0.9% vs +2.3%) was observed, and no statistically significant differences were observed in changes in lipid levels, fasting blood glucose levels, insulin levels, or insulin resistance.
  • SAT abdominal subcutaneous adipose tissue
  • GH growth hormone
  • GHRH GH releasing hormone
  • somatostatin tone which suppresses GH.
  • a number of recent studies have assessed GH treatment in HIV patients with fat accumulation. In 1 study, 325 HIV patients with increased waist: hip ratios and increased VAT measurements received.
  • GH and GHRH GH releasing hormone
  • hypolipidemic agents which are PPAR modulators have been disclosed in WO 91/19702, WO 94/01420, WO 94/13650, WO 95/03038, WO 95/17394, WO 96/04260, WO 96/04261 , WO 96/33998, WO 97/25042, WO 97/36579, WO 98/28534, WO 99/08501 , WO 99/16758, WO 99/19313, WO99/20614, WO 00/23417, WO 00/23445, WO 00/23451 , WO 01/53257.
  • WO 03009841 discloses ula
  • the sodium salts of the compounds of the present invention was difficult to isolate due to rapid degradation while the Calcium salt was poorly absorbed limiting its efficacy and possibility of further development. Further, the calcium salt was also found to degrade on long term storage. It has surprisingly now been found that certain compounds and their selected salts are effective in the treatment of lipohypertrophy, lipoatrophy and metabolic abnormalities in HIV patients.
  • the present invention provides a compound of formula (I) suitable for the treatment and prevention of lipodystrophy.
  • the conditions associated with lipodystrophy includes the symptoms of lipohypertrophy, lipoatrophy and other metabolic abnormalities.
  • the present invention provides a compound of formula (I) for the treatment and prevention or alleviation of symptoms of lipohypertrophy, lipoatrophy and metabolic abnormalities in HIV patient.
  • the present invention provides the administration of compound of formula (I) and their pharmaceutically acceptable salts alone or in combination with other suitable agents as therapeutic agent for the treatment and prevention alleviation of symptoms of lipodystrophy.
  • the present invention provides a suitable composition comprising the compound of formula (1) or their suitable pharmaceutical compositions suitable for the treatment and prevention alleviation of symptoms of lipodystrophy.
  • the present invention provides for certain pharmaceutical salts of compound of formula (I).
  • the present invention provides a compound of formula (1) and their pharmaceutically acceptable salts for the prevention and treatment or alleviation of symptoms of lipodystrophy.
  • the present invention provides a compound of formula (I) and their pharmaceutically acceptable salts for the prevention and treatment or alleviation of symptoms of lipodystrophy caused either because of HIV infection or due to treatment with anti-retrovirals:
  • anti-retrovirals can include HIV-1 protease inhibitors (Pis), Nucleoside reverse transcriptase inhibitors (NRTls), Non-nucleoside Reverse Transcriptase Inhibitors (N RTIs), Fusion Inhibitors, Entry Inhibitors - CCR5 co-receptor antagonist, HIV integrase strand transfer inhibitors etc.
  • the compound of formula (I) neutralizes lipohypertrophy, lipoatrophy and metabolic abnormalities in HIV patient.
  • the present invention also provides a suitable composition comprising compound of formula (I) useful in the treatment or prevention or alleviation of the symptoms of lipodystrophy in HIV infected patients (LDHIV).
  • the present invention describes compound of formula (I) which is suitable for the treatment of lipodystrophy or HIV associated lipodystrophy.
  • 'R' is selected from hydroxy, hydroxyalkyl, acyl, alkoxy, alkylthio, thioalkyl, aryloxy, arylthio and M + represents suitable metal cations such as Na + , K + , Ca +2 , Mg 42 , and the like.
  • 'R' represents thioalkyl, alkoxy or hydroxyalkyl group; In a still preferred embodiment, 'R' represents -SCH 3 or -OCH 3 group.
  • suitable pharmaceutical composition for the treatment of lipodystrophy or HIV associated lipodystrophy comprising the compound of formula (I).
  • the pharmaceutical composition of the present invention comprises compound of formula (I) along with suitable excipients as defined hereinafter for the treatment of lipodystrophy or HIV associated lipodystrophy.
  • the present invention provides a method of treating a subject suffering from lipodystrophy or HIV associated lipodystrophy which comprises treatment of a patient in need of such therapy, with compound of formula (1) or suitable pharmaceutical compositions containing them.
  • the present invention provides use of the compound of formula (I) or their suitable pharmaceutical compositions for the treatment of lipodystrophy or HIV associated lipodystrophy.
  • the present invention provides certain new salts of compound of formula (la)
  • 'R' is selected from hydroxy, hydroxyalkyl, acyl, alkoxy, alkylthio, thioalkyl, aryloxy, arylthio and M + represents suitable metal cations selected from K + , Mg +2 .
  • 'R' represents thioalkyl and alkoxy or hydroxyalkyl group; In a still preferred embodiment, 'R' represents -SCH 3 or -OCH 3 group. In another preferred embodiment, M represents Mg .
  • the effective amount of the said compound of formula (I) is selected from 1 mg to 500 mg preferably 1 mg to 250 mg and more preferably 4 mg to 50 mg.
  • the compound of formula (I) or its suitable salts is administrated orally, intravenously. parentally in the subject who is in need of treatment.
  • the compound of formula (I) is useful for the treatment or prevention or alleviation of the symptoms of lipodystrophy.
  • the compound of formula (I) is useful in the treatment or prevention or alleviation of the symptoms of HIV associated lipodystrophy.
  • the Lipodystrophy is a disorder of fat metabolism which causes lipohypertrophy lipoatrophy and metabolic abnormalities.
  • the compound of formula (1 ) cure or prevent or alleviate at least one symptoms of lipodystrophy including, but not limited to, acting as an agent for lowering &/or control blood glucose levels, an agent used to control lipid levels, e.g., as an agent used to lower control cholesterol, an antioxidant, an appetite suppressing agent, an anti-obesity agent, a probiotic or an anti-inflammatory agent.
  • the compound of formula ( 1) cure or prevent or alleviate at least one symptoms of lipodystrophy including, but not limited to triglyceride level, VLDL level and Apo B level in serum.
  • the compound of formula (1) cure or prevent of lipodystrophy by improving at least one of the condition selected from HDL level, Apo Al level, HOMA of beta cell function derived from c- peptide.
  • the present invention also provides a suitable pharmaceutical composition of compounds of formula (I) or their derivative.
  • the pharmaceutical composition of the present invention essentially comprises of:
  • the suitable stabilizers used in pharmaceutical composition are selected from:
  • the suitable buffering agent are selected from sodium acetate, ammonia solution, ammonium carbonate, sodium borate, adipic Acid, glycine, monosodium glutamate and preferably selected from ammonia solution.
  • the pharmaceutically acceptable excipients are selected at least one from carriers, binders, antioxidant agents, disintegrating agents, wetting agents, lubricating agents, chelating agents, surface active agents, and the like.
  • Diluents include, but are not limited to lactose monohydrate, lactose, polymethacrylates selected from Eudragit, potassium chloride, sulfobutylether b- cyclodextrin, sodium chloride, spray dried lactose, and preferably sulfobutyl ether b- cyclodextrin.
  • Carriers include, but are not limited to lactose, white sugar, sodium chloride, glucose, urea, starch, calcium carbonate and kaolin, crystalline cellulose, and silicic acid.
  • Binders include, but are not limited to carbomers selected from carbopol, gellan, gum Arabic, hydrogenated vegetable oil, polymethacrylates selected from Eudragit, xanthan, lactose and Zein.
  • Antioxidant agents include, but are not limited to, Hypophosphorous acid, Sodium formaldehyde, sodium formaldehylde sulfoxylate, sulfur dioxide, tartaric acid, thymol and methionine.
  • Disintegrating agents include, but are not limited to, bicarbonate salt, chitin, gellan gum, polacrillin potassium and Docusate Sodium.
  • Wetting agents include, but are not limited to, Glycerin, lactose, Docusate Sodium and Glycine
  • Lubricating agents used include, but are not limited to, Glycerin behenate, hydrogenated vegetable oil, sodium stearyl fumarate and Myristic Acid.
  • Chelating agents include, but are not limited to, Maltol and Pentetic Acid.
  • Nonionic surfactant selected from alkyl polyglucosides, cocamide DEA, cocamide MBA, cocamide TEA, decyl maltoside and octyl glucoside;
  • Anionic surfactant selected from arachidic acid and arachidonic acid;
  • Cationic surfactant selected from cetyl trimethylammonium bromide and cetylpyridinium chloride.
  • the formulation is useful for the treatment or prevention or alleviation of the symptoms of lipodystrophy. In a preferred embodiment the said formulation is useful in the treatment or prevention or alleviation of the symptoms of HIV associated lipodystrophy.
  • Lipodystrophy is a disorder of fat metabolism which causes lipohypertrophy, lipoatrophy and metabolic abnormalities. Moreover, lipohypertrophy includes the enlargement of dorsocervical fat pad (commonly called "buffalo hump"), expansion of the circumference of the neck by 5-10 cm, hypertrophy occurs in breast, Central truncal adiposity results from abdominal visceral fat accumulation, symmetric and asymmetric lipomatoses. A rare pattern of lipoaccumulation involving bandlike lipomatosis tissue symmetrically from the breasts, laterally to the axillae, suprapubic fat pads (pubic lipomas) and the development of multiple angiolipomas.
  • dorsocervical fat pad commonly called "buffalo hump”
  • Lipoatrophy includes a temporal wasting and loss of subcutaneous fat from the cheeks (buccal fat pad) produces an emaciated appearance with prominent nasolabial creases, subcutaneous tissue is depleted from the arms, shoulders, thighs, and buttocks (peripheral wasting), with prominence of the superficial veins in these sites.
  • Metabolic abnormalities include augmentation in cholesterol and triglyceride levels and reduced high-density lipoprotein (HDL) cholesterol levels. Insulin resistance, type 2 diabetes mellitus, and lactic academia.
  • HDL high-density lipoprotein
  • the compounds of the present invention due to their beneficial effect on lipodystrophy, will have beneficial effect on Body fat redistribution ( Lioatrophy or Hypertrophy or abnormal distribution), Dyslipidemia, Glucose homeostatis, Proinflammatory conditions, impact on morbidity and mortality, impact on quality of life, impact on patient's reported outcomes like self perception etc
  • HlV-1 HIV type 1
  • NRTIs nucleoside reverse transcriptase inhibitors
  • Pis have a high affinity for the catalytic site of HIV-1 protease, which shares a 60% sequence homology with 2 proteins involved in lipid metabolism, cytoplasmic retinoic acid- binding protein type 1 (CRABP-1 ) and low-density lipoprotein receptor-related protein (LDLR-RP). Inhibition of CRABP-1 impairs the production of retinoic acid, leading to decreased fat storage arid adipocyte apoptosis with the subsequent release of lipids into the circulation. Inhibition of LDLR-RP results in hyperlipidemia secondary to the failure of hepatic and endothelial removal of chylomicrons and triglycerides from the circulation.
  • CRABP-1 cytoplasmic retinoic acid- binding protein type 1
  • LDLR-RP low-density lipoprotein receptor-related protein
  • NRTIs inhibit mtDNA polymerase gamma, leading to mtDNA depletion, respiratory chain dysfunction, and reduced energy production, which, in turn, causes insulin resistance and secondary dyslipidemia.
  • mtDNA mitochondrial DNA
  • hypoxic adipocytes do not take up triglycerides and are resistant to mtDNA-induced damage, except after treatment with NRTIs.
  • the compound of formula (I) or pharmaceutical composition containing the compound of formula (1) cure or prevent or alleviate at least one symptoms of lipodystrophy including, but not limited to, acting as an agent for lowering &/or an agent used to control blood glucose levels, an agent used to control lipid levels, e.g., as an agent used to lower control cholesterol, an antioxidant, an appetite suppressing agent, an anti-obesity agent, an antibiotic/ probiotic or an anti- inflammatory agent..
  • the pharmaceutical composition cure or prevent or alleviate at least one symptoms of lipodystrophy including, but not limited to triglyceride level, VLDL level and Apo B level in serum.
  • the pharmaceutical composition cure or prevent of lipodystrophy by improving at least one of the condition selected from HDL level, Apo Al level, HOMA of beta cell function derived from c-peptide.
  • the compounds according to Formula (I) can be used alone or in combination e.g., as an adjunct therapy, with at least one other therapeutic agent.
  • Compound according to formula (I) can be co-administered with a therapeutic agent used to reduce one or more of the symptoms of lipodystrophy including, but not limited to, an agent used to control blood glucose levels, an agent used to control lipid levels, e.g., an agent used to lower control cholesterol, an antioxidant, an appetite suppressing agent, an anti-obesity agent an antibiotic/ ' probiotic or an anti-inflammatory agent.
  • a therapeutic agent used to reduce one or more of the symptoms of lipodystrophy including, but not limited to, an agent used to control blood glucose levels, an agent used to control lipid levels, e.g., an agent used to lower control cholesterol, an antioxidant, an appetite suppressing agent, an anti-obesity agent an antibiotic/ ' probiotic or an anti-inflammatory agent.
  • Such combination treatment may be adjunct to anti-retroviral therapy.
  • the compound of formula (I) administrated alone or in combination for the treatment of lipohypertrophy, lipoatrophy and Metabolic abnormalities in HIV patient.
  • M+ represents K, Mg
  • Mg can be prepared by the processes disclosed herein below along with suitable modifications known to a skilled person.
  • reaction mixture was stirred under heating, using Dean-stark apparatus, to remove water azeotropically.
  • the reaction mixture was cooled to 50 °C.
  • 319 g anhydrous potassium carbonate was added and stirred at 90-92 °C for 1 hr. Cooled to 65 °C and added 500 g 2-(2-methyl-5-(4-(methylthio)phenyl)-l H-pyrrol-l-yl)ethyl methanesulfonate and 22 g tetra butyl ammonium bromide.
  • Reaction mixture was heated to 87-92 °C and stirred for 46 hrs.
  • the present invention further discloses use of said compound of formula (1) or their suitable pharmaceutical compositions for the treatment of lipohypertrophy, lipoatrophy and metabolic abnormalities in HIV patient.
  • subjects with hypertriglyceridemia in HIV associated lipodystrophy, on treatment with HAART for at least 18 months and satisfying the inclusion and exclusion criteria were enrolled in the study.
  • the subjects received 4 mg of compound of formula (I) tablet orally, once daily for a period of 12 weeks. During this 12-week program, safety parameters were assessed at weeks 2, 6, and 12 and the efficacy was evaluated at week 6 and 12.
  • Test product Compound of formula (I)
  • the primary efficacy endpoint was to assess the percent change in TG levels from baseline to Week 6 and Week 12.
  • the secondary efficacy endpoint was the assessment of LDL, VLDL, HDL, Non HDL cholesterol, Total cholesterol, Apo Al , Apo B, and C-peptide and fasting insulin for HOMA beta and HOMA IR.
  • Haematological examination included haemoglobin, haematocrit, red blood cell (RBC) count, white blood cell (WBC) count with differential (neutrophils, lymphocytes, monocytes, eosinophils and basophils) and platelet count.
  • treatment effect was evaluated using an analysis of variance (ANOVA) model with factors for baseline and treatment.
  • Treatment effects were estimated using the least-square means (LSM) and 95% confidence intervals (Cls) from the ANOVA model.
  • LSM least-square means
  • Cls 95% confidence intervals
  • Compound of formula (1) is divalent magnesium salt of carboxylic acid in the form of white, amorphous powder, which is freely soluble in dimethyl sulfoxide, dichloromethane, slightly soluble in methanol and insoluble in water.
  • the drug was supplied as uncoated tablets of 4 mg of the active ingredient.
  • the primary efficacy endpoint was fo determine the percent change in TG levels from baseline to Week 6 and Week 12.
  • the secondary efficacy endpoint was to determine the percent change in LDL
  • the demographic and baseline characteristics were summarized for compound of formula (I) 4 mg treatment arm.
  • the mean, median, standard deviation (SD) and range were tabulated.
  • the frequencies were computed.
  • the primary efficacy variable was the reduction in TG at Week 6 and Week 12 of the treatment period compared with baseline.
  • the change from baseline was determined as the difference between the means for the treatment period (Weeks 6 / Weeks 12) and the baseline.
  • treatment effect was evaluated using an analysis of variance (ANOVA) model with factors for baseline and treatment.
  • Treatment effects were estimated using the least-square means (LSM) and 95% confidence intervals (CIs) from the ANOVA model.
  • LSM least-square means
  • CIs 95% confidence intervals
  • Intent-to-treat (ITT) and/or Per Protocol (PP) analysis were carried out for the study.
  • the PP analysis was considered definitive while the ITT analysis was considered supportive during the trial analysis.
  • EHT004 One subject identified as EHT004 in the study, a 35-year-old male, was reported with abnormally low levels of HDL (3.95 mg/L) and LDL (6.25 mg/L) at Visit 1. Though this subject completed the study and was assessable for efficacy, it was decided to exclude this subject from the efficacy analyses. Therefore a total of 49 subjects were analyzed for efficacy. .
  • LSM least square means
  • N number of subjects in the treatment group
  • n number of subjects having non-missing baseline and post-baseline values
  • SD standard deviation
  • SE standard error
  • HDL high density lipoprotein.
  • HOMA homeostasis model assessment
  • IR insulin resistance
  • LSM least square means
  • N number of subjects in the treatment group
  • n number of subjects having non-missing baseline and post-baseline values
  • SD standard deviation
  • SE standard error
  • LSM least square means
  • N number of subjects in the treatment group
  • n number of subjects having non-missing baseline and post-baseline values
  • SD standard deviation
  • SE standard error
  • Beta-cell function derived from Insulin There was an increase in HOMA of Beta-cell function derived from Insulin after treatment with compound of formula (1).
  • the percent change in the HOMA of Beta-cell function derived from Insulin from baseline at Week 6 and Week 12 was statistically significant (52.50 ⁇ 14.94 and 45.64 ⁇ 6.22, respectively [p-value: 0.0010 and ⁇ 0.0001 , respectiveIy])(TabIe 5).
  • HOMA homeostasis model assessment
  • LSM least square means
  • N number of subjects in the treatment group
  • n number of subjects having non-missing baseline and post- baseline values
  • SD standard deviation
  • SE standard error
  • Beta-cell function derived from C-peptide from baseline following administration of compound of formula (I) 4 mg at Week 6 and Week 12 (68.25 ⁇ 25.58 and 71 .67 ⁇ 16.20, respectively [p-value: 0.0104 and O.0001 , respectively]).
  • the compound of the present invention including pharmaceutical compositions containing the same was found to be useful for the treatment of lipohypertrophy, lipoatrophy and Metabolic abnormalities in HIV patients.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Saccharide Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Ceramic Products (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention provides a therapeutic compound of formula (I) and their pharmaceutically acceptable salts for the prevention and treatment of lipodystrophy caused because of HIV infection or combination therapy of HIV-1 protease inhibitors (Pis) and/or reverse transcriptase inhibitors (nRTIs) by neutralizing lipohypertrophy, lipoatrophy and metabolic abnormalities in HIV patient.

Description

TREATMENT FOR LIPODYSTROPHY
Field of the invention
The present invention is related to the development of therapeutic compound for prevention and treatment of lipodystrophy. In particular the invention relates to the development of therapeutic compound for prevention and treatment of lipodystrophy in HIV -infected patients (LDHIV). Specifically, the present invention further provides a suitable composition useful in the treatment or prevention or alleviation of the symptoms of lipodystrophy in HIV infected patients (LDHIV)
Background of the invention
Lipodystrophy is a very dreadful disease and has become a major global health problem. It is a disorder of fat metabolism which causes lipohypertrophy, Lipoatrophy and Metabolic abnormalities. Moreover, lipohypertrophy includes the enlargement of dorsocervical fat pad (commonly called "buffalo hump"), expansion of the circumference of the neck by 5-10 cm, hypertrophy occuring in breast, central truncal adiposity resulting from abdominal visceral fat accumulation, symmetric and asymmetric lipomatoses. A rare pattern of lipoaccumulation involves formation of band like lipomatosis tissue symmetrically from the breasts, laterally to the axillae, Suprapubic fat pads (pubic lipomas) and the development of multiple angiolipomas.
Lipoatrophy includes a temporal wasting and loss of subcutaneous fat from the cheeks (buccal fat pad) which produces an emaciated appearance with prominent nasolabial creases. Further subcutaneous tissue is depleted from the arms, shoulders, thighs, and buttocks (peripheral wasting), with prominence of the superficial veins in these sites.
Metabolic abnormalities include augmentation in cholesterol and triglyceride levels and reduced high-density lipoprotein (HDL) cholesterol levels, Insulin resistance, type 2 diabetes mellitus, and lactic academia.
Lipodystrophy is very commonly associated with the HIV patients who are being treated anti-retroviral medicines. Such medicines can include HIV-1 protease inhibitors (Pis), Nucleoside reverse transcriptase inhibitors (NRTIs), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Fusion Inhibitors, Entry Inhibitors - CCR5 co-receptor antagonist, HIV integrase strand transfer inhibitors etc. These medicines improve the survival of the patient but also produce lipohypertrophy, Lipoatrophy and other Metabolic abnormalities. HIV-1 protease inhibitors (Pis) appear to be the strongest link to lipodystrophy in HIV -infected patients LDH1V as it inhibits maturation of sterol response element binding proteins (SREBP), which affect intracellular fatty acid and glucose metabolism and adipocyte differentiation (Mallon et al, J Infect Dis, 2005). Furthermore, the Pis also down-regulate peroxisome proliferator-activated receptor gamma (PPAR γ), an important nuclear transcription factor that is affected by SREBPs and is necessary for adipocyte differentiation and function and fatty acid metabolism.
Other factors, such as duration of HIV infection, age, and gender, may also contribute to the risk of development of LDHIV. The molecular basis of LDH1V is still remains unknown and no specific therapy is available for LDHIV.
Reverse transcriptase inhibitors (nRTls) like stavudine, didanosine and zidovudine may cause mitochondrial toxicity by inhibiting mitochondrial DNA polymerase-yin fat and other tissues and thus interfering with respiratory chain complexes. The result is impaired fatty acid oxidation and intracellular accumulation of triglycerides and lactate
In addition, lipodystrophy is also observed in acute HIV infection, lending support to a direct viral role as well. Potential host risk factors include age, sex, and race or ethnicity. Lipodystrophy is more common in older patients; fat accumulation is more common in women and lipoatrophy in men; and non-Hispanic black patients appear to be at lower risk of lipoatrophy. A genetic component is indicated by a recent analysis in AIDS Clinical Trials Group (ACTG) , study 5005s, suggesting either predisposition or protection associated with mitochondrial DNA polymorphisms.
Hulgan et al, J Infect Dis, 2008 describes that patients homozygous for C/C at the HFE187 locus (n = 71) had a 0.6-kg and 12.5% loss of limb fat at weeks 48 to 64, with 37 (52%) of the 71 patients diagnosed with clinical lipoatrophy. By comparison, heterozygous patients with HFE187C/G had a 0.2-kg and 6.1% increase in limb fat, with 6 (26%) of 23 patients having clinical lipoatrophy (P < .05 for all comparisons).
A number of strategies for reducing central obesity have been investigated such as stopping PI treatment but it is not effective. Changes in diet and exercise have produced improvements, but adherence to a regimen of lifestyle change is difficult for most patients. Liposuction may be applied particularly with dorsocervical fat accumulation, i.e., "buffalo hump". It is evident from the several studies that thiazolidinediones show no change in VAT (Pathogenesis and treatment of lipodystrophy, vol.16, issue 4, Oct/November,2004)
Testosterone replacement to physiologic levels reduces visceral adipose tissue (VAT), total fat, and abdominal fat and improves insulin sensitivity and lipid profile in older, non-HI.V-infected men with upper body obesity and low testosterone levels. In a recent study, 88 HIV-infected men with central obesity (waist circumference >100 cm) and low testosterone levels (< 400 ng/dL) underwent randomization to testosterone as a transdermal gel at a dose of 10 g daily or placebo for 24 weeks (Bhasin et al, J Clin Endocrinol Metab, 2007). The testosterone group had statistically significant reductions in abdominal fat (-1 .5% vs +4.3%), abdominal subcutaneous adipose tissue (SAT) (- 7.2% vs +8.1 %), trunk fat (-9.9% vs +4.6%), and limb fat (-10.1 % vs +3.1 %); the latter finding is of potential concern in a population predisposed to lipoatrophy. No statistically significant difference in change in VAT (+0.9% vs +2.3%) was observed, and no statistically significant differences were observed in changes in lipid levels, fasting blood glucose levels, insulin levels, or insulin resistance.
Like testosterone, growth hormone (GH) has fat-oxidizing and lipolytic properties. A substantial proportion of HIV patients with central obesity (approximately 30%-40%) have impaired GH biology, including reduced GH mass secretion, reduced response to GH releasing hormone (GHRH) and free fatty acids, and increased somatostatin tone, which suppresses GH. A number of recent studies have assessed GH treatment in HIV patients with fat accumulation. In 1 study, 325 HIV patients with increased waist: hip ratios and increased VAT measurements received.
Although, the growth hormone (GH) and GH releasing hormone (GHRH) therapies show some promising result as they have fat-oxidizing and lipolytic properties however, there are limitations to their use. They are parenteral therapies and either expensive (rhGH) or not FDA-approved (tesamorelin). Thus far, there is evidence of waning durability of the reduction in VAT after their discontinuation, short-term increases in insulin resistance with rhGH, and small short-term reductions.
Recent research publications have shown the use of two lipid-lowering classes of drugs, statins and fibrates, antiretroviral switching strategies and use of insulin- sensitising drugs as having some beneficial effect on lipodystrophy. However, no single therapy is able to reach desirable clinical end point for HIV associated lipodystrophy. Hence it is desirable to develop a compound which can overcome the above discussed drawback associated with prior art and develop a therapy for HIV associated lipodystrophy.
Hypolipidemic agents which are PPAR modulators have been disclosed in WO 91/19702, WO 94/01420, WO 94/13650, WO 95/03038, WO 95/17394, WO 96/04260, WO 96/04261 , WO 96/33998, WO 97/25042, WO 97/36579, WO 98/28534, WO 99/08501 , WO 99/16758, WO 99/19313, WO99/20614, WO 00/23417, WO 00/23445, WO 00/23451 , WO 01/53257.
WO 03009841 discloses ula
Figure imgf000005_0001
These compounds are reported to be hypolipidaemic agents. This document also discloses sodium and calcium salts of some of the compounds disclosed therein.
However, the sodium salts of the compounds of the present invention was difficult to isolate due to rapid degradation while the Calcium salt was poorly absorbed limiting its efficacy and possibility of further development. Further, the calcium salt was also found to degrade on long term storage. It has surprisingly now been found that certain compounds and their selected salts are effective in the treatment of lipohypertrophy, lipoatrophy and metabolic abnormalities in HIV patients.
Embodiments of the invention
In an embodiment the present invention provides a compound of formula (I) suitable for the treatment and prevention of lipodystrophy.
In an embodiment, the conditions associated with lipodystrophy includes the symptoms of lipohypertrophy, lipoatrophy and other metabolic abnormalities.
In another embodiment, the present invention provides a compound of formula (I) for the treatment and prevention or alleviation of symptoms of lipohypertrophy, lipoatrophy and metabolic abnormalities in HIV patient.
In yet another embodiment the present invention provides the administration of compound of formula (I) and their pharmaceutically acceptable salts alone or in combination with other suitable agents as therapeutic agent for the treatment and prevention alleviation of symptoms of lipodystrophy. In yet another embodiment the present invention provides a suitable composition comprising the compound of formula (1) or their suitable pharmaceutical compositions suitable for the treatment and prevention alleviation of symptoms of lipodystrophy.
In another embodiment, the present invention provides for certain pharmaceutical salts of compound of formula (I).
Summary of the invention
The present invention provides a compound of formula (1) and their pharmaceutically acceptable salts for the prevention and treatment or alleviation of symptoms of lipodystrophy. The present invention provides a compound of formula (I) and their pharmaceutically acceptable salts for the prevention and treatment or alleviation of symptoms of lipodystrophy caused either because of HIV infection or due to treatment with anti-retrovirals: Such anti-retrovirals can include HIV-1 protease inhibitors (Pis), Nucleoside reverse transcriptase inhibitors (NRTls), Non-nucleoside Reverse Transcriptase Inhibitors (N RTIs), Fusion Inhibitors, Entry Inhibitors - CCR5 co-receptor antagonist, HIV integrase strand transfer inhibitors etc. or combination therapy involving one or more anti-retrovirals. The compound of formula (I) neutralizes lipohypertrophy, lipoatrophy and metabolic abnormalities in HIV patient. Moreover, the present invention also provides a suitable composition comprising compound of formula (I) useful in the treatment or prevention or alleviation of the symptoms of lipodystrophy in HIV infected patients (LDHIV).
In a further embodiment are disclosed certain new salts corresponding to the compound of formula (I) wherein M represents or Mg.
Description of the Invention
The present invention describes compound of formula (I) which is suitable for the treatment of lipodystrophy or HIV associated lipodystrophy.
Figure imgf000006_0001
wherein 'R' is selected from hydroxy, hydroxyalkyl, acyl, alkoxy, alkylthio, thioalkyl, aryloxy, arylthio and M+ represents suitable metal cations such as Na+, K+, Ca+2, Mg42 , and the like.
In a preferred embodiment, 'R' represents thioalkyl, alkoxy or hydroxyalkyl group; In a still preferred embodiment, 'R' represents -SCH3 or -OCH3 group.
In an embodiment is provided suitable pharmaceutical composition for the treatment of lipodystrophy or HIV associated lipodystrophy comprising the compound of formula (I). The pharmaceutical composition of the present invention comprises compound of formula (I) along with suitable excipients as defined hereinafter for the treatment of lipodystrophy or HIV associated lipodystrophy.
In another embodiment, the present invention provides a method of treating a subject suffering from lipodystrophy or HIV associated lipodystrophy which comprises treatment of a patient in need of such therapy, with compound of formula (1) or suitable pharmaceutical compositions containing them.
In a further embodiment the present invention provides use of the compound of formula (I) or their suitable pharmaceutical compositions for the treatment of lipodystrophy or HIV associated lipodystrophy.
In an embodiment the present invention provides certain new salts of compound of formula (la)
Figure imgf000007_0001
(la)
wherein 'R' is selected from hydroxy, hydroxyalkyl, acyl, alkoxy, alkylthio, thioalkyl, aryloxy, arylthio and M+ represents suitable metal cations selected from K+, Mg+2.
In a preferred embodiment, 'R' represents thioalkyl and alkoxy or hydroxyalkyl group; In a still preferred embodiment, 'R' represents -SCH3 or -OCH3 group. In another preferred embodiment, M represents Mg .
The effective amount of the said compound of formula (I) is selected from 1 mg to 500 mg preferably 1 mg to 250 mg and more preferably 4 mg to 50 mg. The compound of formula (I) or its suitable salts is administrated orally, intravenously. parentally in the subject who is in need of treatment.
In an embodiment the compound of formula (I) is useful for the treatment or prevention or alleviation of the symptoms of lipodystrophy. In a preferred embodiment the compound of formula (I) is useful in the treatment or prevention or alleviation of the symptoms of HIV associated lipodystrophy. In such embodiment the Lipodystrophy is a disorder of fat metabolism which causes lipohypertrophy lipoatrophy and metabolic abnormalities.
In an embodiment the compound of formula (1 ) cure or prevent or alleviate at least one symptoms of lipodystrophy including, but not limited to, acting as an agent for lowering &/or control blood glucose levels, an agent used to control lipid levels, e.g., as an agent used to lower control cholesterol, an antioxidant, an appetite suppressing agent, an anti-obesity agent, a probiotic or an anti-inflammatory agent. In another embodiment the the compound of formula ( 1) cure or prevent or alleviate at least one symptoms of lipodystrophy including, but not limited to triglyceride level, VLDL level and Apo B level in serum. In another embodiment the compound of formula (1) cure or prevent of lipodystrophy by improving at least one of the condition selected from HDL level, Apo Al level, HOMA of beta cell function derived from c- peptide.
In an embodiment the present invention also provides a suitable pharmaceutical composition of compounds of formula (I) or their derivative. The pharmaceutical composition of the present invention essentially comprises of:
- the pharmaceutically active substance;
a suitable buffering agent;
- a suitable stabilizer;
- optionally with one or more pharmaceutically acceptable excipients.
The suitable stabilizers used in pharmaceutical composition are selected from
Polacrilin potassium, Potassium chloride, Sodium stearyl fumarate and preferably selected from Sodium stearyl fumarate. The suitable buffering agent are selected from sodium acetate, ammonia solution, ammonium carbonate, sodium borate, adipic Acid, glycine, monosodium glutamate and preferably selected from ammonia solution.
The pharmaceutically acceptable excipients are selected at least one from carriers, binders, antioxidant agents, disintegrating agents, wetting agents, lubricating agents, chelating agents, surface active agents, and the like.
Diluents include, but are not limited to lactose monohydrate, lactose, polymethacrylates selected from Eudragit, potassium chloride, sulfobutylether b- cyclodextrin, sodium chloride, spray dried lactose, and preferably sulfobutyl ether b- cyclodextrin. Carriers include, but are not limited to lactose, white sugar, sodium chloride, glucose, urea, starch, calcium carbonate and kaolin, crystalline cellulose, and silicic acid. Binders include, but are not limited to carbomers selected from carbopol, gellan, gum Arabic, hydrogenated vegetable oil, polymethacrylates selected from Eudragit, xanthan, lactose and Zein. Antioxidant agents include, but are not limited to, Hypophosphorous acid, Sodium formaldehyde, sodium formaldehylde sulfoxylate, sulfur dioxide, tartaric acid, thymol and methionine. Disintegrating agents include, but are not limited to, bicarbonate salt, chitin, gellan gum, polacrillin potassium and Docusate Sodium. Wetting agents include, but are not limited to, Glycerin, lactose, Docusate Sodium and Glycine, Lubricating agents used include, but are not limited to, Glycerin behenate, hydrogenated vegetable oil, sodium stearyl fumarate and Myristic Acid. Chelating agents include, but are not limited to, Maltol and Pentetic Acid. Surface active agents include but are not limited to, Nonionic surfactant selected from alkyl polyglucosides, cocamide DEA, cocamide MBA, cocamide TEA, decyl maltoside and octyl glucoside; Anionic surfactant selected from arachidic acid and arachidonic acid; Cationic surfactant selected from cetyl trimethylammonium bromide and cetylpyridinium chloride.
In an embodiment the formulation is useful for the treatment or prevention or alleviation of the symptoms of lipodystrophy. In a preferred embodiment the said formulation is useful in the treatment or prevention or alleviation of the symptoms of HIV associated lipodystrophy.
Lipodystrophy is a disorder of fat metabolism which causes lipohypertrophy, lipoatrophy and metabolic abnormalities. Moreover, lipohypertrophy includes the enlargement of dorsocervical fat pad (commonly called "buffalo hump"), expansion of the circumference of the neck by 5-10 cm, hypertrophy occurs in breast, Central truncal adiposity results from abdominal visceral fat accumulation, symmetric and asymmetric lipomatoses. A rare pattern of lipoaccumulation involving bandlike lipomatosis tissue symmetrically from the breasts, laterally to the axillae, suprapubic fat pads (pubic lipomas) and the development of multiple angiolipomas.
Lipoatrophy includes a temporal wasting and loss of subcutaneous fat from the cheeks (buccal fat pad) produces an emaciated appearance with prominent nasolabial creases, subcutaneous tissue is depleted from the arms, shoulders, thighs, and buttocks (peripheral wasting), with prominence of the superficial veins in these sites.
Metabolic abnormalities include augmentation in cholesterol and triglyceride levels and reduced high-density lipoprotein (HDL) cholesterol levels. Insulin resistance, type 2 diabetes mellitus, and lactic academia.
The compounds of the present invention due to their beneficial effect on lipodystrophy, will have beneficial effect on Body fat redistribution ( Lioatrophy or Hypertrophy or abnormal distribution), Dyslipidemia, Glucose homeostatis, Proinflammatory conditions, impact on morbidity and mortality, impact on quality of life, impact on patient's reported outcomes like self perception etc
Moreover, the precise mechanisms underlying this syndrome are not well understood, several hypotheses based on in vitro and human studies may explain the pathogenesis of the changes. Some experts presently believe that HIV type 1 (HlV-1 ) protease inhibitors (Pis) and nucleoside reverse transcriptase inhibitors (NRTIs), especially stavudine and zidovudine, are implicated as follows:
(i) decreased production of retinoic acid and triglyceride uptake: Pis have a high affinity for the catalytic site of HIV-1 protease, which shares a 60% sequence homology with 2 proteins involved in lipid metabolism, cytoplasmic retinoic acid- binding protein type 1 (CRABP-1 ) and low-density lipoprotein receptor-related protein (LDLR-RP). Inhibition of CRABP-1 impairs the production of retinoic acid, leading to decreased fat storage arid adipocyte apoptosis with the subsequent release of lipids into the circulation. Inhibition of LDLR-RP results in hyperlipidemia secondary to the failure of hepatic and endothelial removal of chylomicrons and triglycerides from the circulation.
(ii) inhibition of mitochondrial DNA (mtDNA) polymerase gamma: NRTIs inhibit mtDNA polymerase gamma, leading to mtDNA depletion, respiratory chain dysfunction, and reduced energy production, which, in turn, causes insulin resistance and secondary dyslipidemia. Interestingly, mtDNA is depleted only at normal oxygen levels— hypoxic adipocytes do not take up triglycerides and are resistant to mtDNA-induced damage, except after treatment with NRTIs.
(iii) inhibition of lipid metabolism: Some Pis, particularly ritonavir, inhibit cytochrome P450 3A, a key enzyme in lipid metabolism.
(iv) prevention of the development of adipocytes: Saquinavir, ritonavir, and nelfinavir (all Pis) directly inhibit the development of adipocytes from stem cells and increase the metabolic destruction of fat in existing adipocytes.
In an embodiment the compound of formula (I) or pharmaceutical composition containing the compound of formula (1) cure or prevent or alleviate at least one symptoms of lipodystrophy including, but not limited to, acting as an agent for lowering &/or an agent used to control blood glucose levels, an agent used to control lipid levels, e.g., as an agent used to lower control cholesterol, an antioxidant, an appetite suppressing agent, an anti-obesity agent, an antibiotic/ probiotic or an anti- inflammatory agent.. In another embodiment the pharmaceutical composition cure or prevent or alleviate at least one symptoms of lipodystrophy including, but not limited to triglyceride level, VLDL level and Apo B level in serum. In another embodiment the pharmaceutical composition cure or prevent of lipodystrophy by improving at least one of the condition selected from HDL level, Apo Al level, HOMA of beta cell function derived from c-peptide.
In another embodiment the compounds according to Formula (I) can be used alone or in combination e.g., as an adjunct therapy, with at least one other therapeutic agent. Compound according to formula (I) can be co-administered with a therapeutic agent used to reduce one or more of the symptoms of lipodystrophy including, but not limited to, an agent used to control blood glucose levels, an agent used to control lipid levels, e.g., an agent used to lower control cholesterol, an antioxidant, an appetite suppressing agent, an anti-obesity agent an antibiotic/'probiotic or an anti-inflammatory agent. Such combination treatment may be adjunct to anti-retroviral therapy. In a preferred embodiment the compound of formula (I) administrated alone or in combination for the treatment of lipohypertrophy, lipoatrophy and Metabolic abnormalities in HIV patient. The compound of the present invention when M+ represents K, Mg can be prepared by the processes disclosed herein below along with suitable modifications known to a skilled person.
Example 1
Preparation of (S)-a-Ethoxy-4-[2-[-methyl-5-[4-(methylthio)phenyl]-]H-pyrrol-l - yl]ethoxy]benzene-propanoic acid ethyl ester
In a dry, 5 L round bottom flask 2.1 L toluene was taken under nitrogen. To this 366.1 g ethyl (S)- a-2-ethoxy-3-(4-hydroxyphenyl)propionate was added at room temperature.
The reaction mixture was stirred under heating, using Dean-stark apparatus, to remove water azeotropically. The reaction mixture was cooled to 50 °C. To this was added 319 g anhydrous potassium carbonate and stirred at 90-92 °C for 1 hr. Cooled to 65 °C and added 500 g 2-(2-methyl-5-(4-(methylthio)phenyl)-l H-pyrrol-l-yl)ethyl methanesulfonate and 22 g tetra butyl ammonium bromide. Reaction mixture was heated to 87-92 °C and stirred for 46 hrs. Cooled to 70-75 °C, added 1 .5 L toluene, charcoalised using 75 g charcoal and cooled to room temperature. Filtrate washed with alkaline solution, washed with water, dried over sodium sulfate and concentrated under vacuum to obtain (S)- -Ethoxy-4-[2-[-methyl-5-[4-(methylthio)phehyl]-lH-pyrrol-l - yl]ethoxy]benzene-propanoic acid ethyl ester.
Yield: 650 g, HPLC purity: 84.10 %; % Yield 76.0 %.
Example 2
Preparation of (S)-a-Ethoxy-4-[2-[-methyl-5-[4-(methylthio)phenyl]-lH-pyrrol-l- yljethoxy] benzenepropanoic acid magnesium salt.
In a dry, 250 mL round bottom flask 80 mL methanol was taken. To this 20 g (S)-a-ethoxy-4-[2-[-methyl-5-[4-(methylthio)phenyl]-lH-pyrrol-l -yl]ethoxy]benzene- propanoic acid ethyl ester was added at room temperature, under nitrogen. To this 1.89 g sodium hydroxide dissolved in 20 mL water was added and stirred at room temperature for 3 hours to complete hydrolysis. Solvent was removed under reduced pressure. 150 mL water was added to concentrate the material. Impurity was removed by solvent washing. To aqueous layer was added 5 g magnesium acetate tetra hydrate (dissolved in 20 mL water) and stirred with for 15 min. Sticky material was extracted with dichloromethane and subsequently add n-heptane to precipitate (S)-a-ethoxy-4- P T/IN2012/000069
[2-[-methyl-5-[4-(methylthio)phenyl]-lH-pyrrol-] -yl]ethoxy]benzenepropanoic acid magnesium salt. Solid was filtered, and dried.
Yield: 10.3 g; HPLC Purity: 98.32 %; Chiral purity: 97.64 %.
Following the process similar to those described in Examples 1 & 2 the following batches of )-a-Ethoxy-4-[2-[-methyl-5-[4-(methylthio)phenyl]-l H-pyrrol-l - yl]ethoxy] benzenepropanoic acid magnesium salt were prepared.
Figure imgf000013_0001
The present invention further discloses use of said compound of formula (1) or their suitable pharmaceutical compositions for the treatment of lipohypertrophy, lipoatrophy and metabolic abnormalities in HIV patient.
Example 9
(S)-a-Ethoxy-4-[2-[-methyl-5-[4-(methylthio)phenyl]-lH-pyrrol-l -yl]ethoxy]
benzenepropanoic acid potassium salt.
In a dry, 250 mL round bottom flask 72 mL ethyl acetate was taken. To this 10 g (S)-(-)a-l -phenylethylamine salt of (S)- a-ethoxy-4-[2-[-methyl-5-[4-(methylthio) phenyl]- lH-pyrrol-l -yl]ethoxy]benzene -propanoic acid was added at room temperature and subsequently 50 mL water and 4.8 mL dilute hydrochloric acid (water 1 : 1 :35% HC1) was added and stirred at room temperature till solid was dissolved. Layer was separated and organic layer was washed with water, dried over sodium sulfate and solvent removed. 9.2 g oily mass obtained. To this was added 50 mL methanol and stirred under nitrogen. To this was added 1 .81 g potassium t-butoxide and was stirred at room temperature for 15 min. Solvent removed and added n-Hexane. Again n-hexane was removed and added methanol. Solvent removed under vacuum. Hygroscopic material obtained. Dried it under vacuum to get (S)- a-ethoxy-4-[2-[- methyl-5-[4-(methylthio)phenyl]-lH-pyrrol-l -yl]ethoxy]benzenepropanoic acid potassium salt.
Yield- 7.6 g, (92.77 %), HPLC Purity 98.60 %, Chiral purity 99.56 %
Example 10
Title of Study: A Prospective, Multi-Centric, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of 4 mg of compound of formula (I) in
Hypertriglyceridemia in HIV Associated Lipodystrophy.
Objectives: The objective of this study was to evaluate the safety and efficacy of 4 mg of compound of formula (1) in hypertriglyceridemia in HIV associated lipodystrophy.
Methodology: This was a prospective, multi-centric, open-label, single arm study to evaluate the safety and efficacy of 4 mg of compound of formula (1) in hypertriglyceridemia in HIV associated lipodystrophy.
After obtaining informed written consent, subjects with hypertriglyceridemia in HIV associated lipodystrophy, on treatment with HAART for at least 18 months and satisfying the inclusion and exclusion criteria were enrolled in the study. The subjects received 4 mg of compound of formula (I) tablet orally, once daily for a period of 12 weeks. During this 12-week program, safety parameters were assessed at weeks 2, 6, and 12 and the efficacy was evaluated at week 6 and 12.
Number of patients: Planned: 50, Analyzed: 50
Test product: Compound of formula (I)
Dose 4 mg
Duration of treatment: 12 weeks
Mode of administration: Oral
Batch number: EMK328
Criteria for evaluation: Efficacy:
The primary efficacy endpoint was to assess the percent change in TG levels from baseline to Week 6 and Week 12. The secondary efficacy endpoint was the assessment of LDL, VLDL, HDL, Non HDL cholesterol, Total cholesterol, Apo Al , Apo B, and C-peptide and fasting insulin for HOMA beta and HOMA IR.
Safety: Clinical examination and recording of adverse events (AEs) was done on all visits. Electrocardiogram was recorded at screening visit and at Week 12. Urine pregnancy test was conducted at screening visit
Haematological examination included haemoglobin, haematocrit, red blood cell (RBC) count, white blood cell (WBC) count with differential (neutrophils, lymphocytes, monocytes, eosinophils and basophils) and platelet count.
Biochemistry tests included AST, ALT, ALP, total bilirubin, serum proteins, total albumin and globulin, γ- GTT, BUN, Serum creatinine, serum uric acid, CPK, and urine R/Ms (including microalbuminuria and ketonuria).
All laboratory parameters were evaluated at enrolment visit (Week 0) and at Weeks 2, 6, and 12.
Statistical methods
For the efficacy endpoints, treatment effect was evaluated using an analysis of variance (ANOVA) model with factors for baseline and treatment. Treatment effects were estimated using the least-square means (LSM) and 95% confidence intervals (Cls) from the ANOVA model. Statistical significance was defined as a two-sided p-value <0.05. All other secondary endpoints were analyzed using appropriate statistical methods.
For safety analysis the frequency tabulations of abnormal physical examination and abnormal clinical laboratory parameters were presented for each visit. Summary statistics for clinical laboratory parameters and vital signs were presented for each visit.
A list of concomitant medications taken during the study period was summarised.
Adverse events were coded using the Medical Dictionary for Regulatory
Activities (MedDRA) (Version 14). Adverse events and SAEs were summarized overall, by system organ class (SOC) and by MedDRA preferred term for treatment emergent adverse events (TEAEs). All AEs, including those arising before or after treatment was included in the listings. Separate listings were provided for SAEs and
AEs leading to discontinuation from the study.
STUDY DESIGN
This was a safety and efficacy study to evaluate 4 mg of compound of formula
(I) in hypertriglyceridemia in HIV associated lipodystrophy. This was exploratory proof of concept study designed to assess the proof of safety and efficacy in intended population. The results of compound of formula (1) from phase II studies in Dyslipidemia subjects demonstrated that compound of formula (I) 4 mg is well tolerated and effective at once daily dosing. Phase I study demonstrated food significantly affects absorption of compound of formula (1), so drug was recommended to be consumed preferably in fasting condition. Based upon these observations 4 mg once daily in fasted condition was selected for present study
SELECTION OF STUDY POPULATION
Inclusion Criteria
Subjects who satisfied all of the following criteria were eligible for enrolment in the study:
1. Males and females aged 1 8- 65 years.
2. Confirmed diagnosis of HI VI and on HAART for at least 18 months.
3. On stable ART regimen for at least 8 weeks prior to inclusion in the study and ART regimen not expected to change in next 3 months.
4. Subjects clinically diagnosed as HIV lipodystrophy (at least 1 moderate or severe lipodystrophy feature identified by doctor and patient, except isolated abdominal obesity)
5. Triglycerides >200 to 500 mg %.
6. CD4 count of >50/mm3
7. Subject who had given informed consent for participation in this trial.
TREATMENTS
Treatments Administered
The study had a single arm. Subjects received 4 mg of compound of formula (I) orally once daily in the morning before breakfast, for a period of 12 weeks.
Identity of Investigational Product(s)
Compound of formula (1) is divalent magnesium salt of carboxylic acid in the form of white, amorphous powder, which is freely soluble in dimethyl sulfoxide, dichloromethane, slightly soluble in methanol and insoluble in water. The drug was supplied as uncoated tablets of 4 mg of the active ingredient.
Supply from batch no EMK328 was used during the study. The study drug was manufactured and packaged in cGMP facility. Primary Efficacy Variable(s)
The primary efficacy endpoint was fo determine the percent change in TG levels from baseline to Week 6 and Week 12.
Secondary Efficacy Variables
The secondary efficacy endpoint was to determine the percent change in LDL,
VLDL, HDL, total cholesterol, non-HDL Cholesterol (measured value), Apo Al , and Apo B, C-peptide and fasting insulin for HOMA beta and HOMA 1R levels from baseline to Week 6 and Week 12.
STATISTICAL METHODS PLANNED IN THE PROTOCOL AND DETERMINATION OF SAMPLE SIZE
Statistical and Analytical Plans
The demographic and baseline characteristics were summarized for compound of formula (I) 4 mg treatment arm. For continuous measurements such as age, the mean, median, standard deviation (SD) and range were tabulated. For categorical measurements such as gender, the frequencies were computed.
Efficacy Analyses:
The primary efficacy variable was the reduction in TG at Week 6 and Week 12 of the treatment period compared with baseline. The change from baseline was determined as the difference between the means for the treatment period (Weeks 6 / Weeks 12) and the baseline.
For the efficacy endpoints, treatment effect was evaluated using an analysis of variance (ANOVA) model with factors for baseline and treatment. Treatment effects were estimated using the least-square means (LSM) and 95% confidence intervals (CIs) from the ANOVA model. Statistical significance was defined as a two-sided p-value <0.05. All other secondary endpoints were analyzed using appropriate statistical methods.
Intent-to-treat (ITT) and/or Per Protocol (PP) analysis were carried out for the study. The PP analysis was considered definitive while the ITT analysis was considered supportive during the trial analysis. EFFICACY RESULTS AND TABULATIONS OF INDIVIDUAL PATIENT DATA Analysis of Efficacy
One subject identified as EHT004 in the study, a 35-year-old male, was reported with abnormally low levels of HDL (3.95 mg/L) and LDL (6.25 mg/L) at Visit 1. Though this subject completed the study and was assessable for efficacy, it was decided to exclude this subject from the efficacy analyses. Therefore a total of 49 subjects were analyzed for efficacy. .
Primary Endpoints
The percent change from baseline in serum TG levels at Week 6 and Week 12 following compound of formula (I) 4 mg was statistically significant (-40.98±4.89 and - 45.1 1 ±3.60, respectively [p-value: <0.000 L each]) (Table 1 ).
Figure imgf000018_0001
2 000069
Figure imgf000019_0001
Secondary End points
HDL Cholesterol:
There was an increase in the HDL cholesterol levels following administration of compound of formula (I) 4 mg. The percent change from baseline in HDL cholesterol following compound of formula (1) 4 mg at Week 6 and Week 12 was statistically significant (29.92±5.73 and 34.56±6.13, respectively [p-value: O.OOOl each]) (Table 2).
Figure imgf000020_0001
Table 2: Analysis of change in HDL Cholesterol (mg/dL) from baseline by visit
COMPOUND OF
FORMULA(I) 4 mg
Laboratory Test (Unit) Visit (N=49)
p-values O.0001
Key to abbreviations: LSM = least square means; N = number of subjects in the treatment group; n = number of subjects having non-missing baseline and post-baseline values; SD = standard deviation; SE = standard error; HDL = high density lipoprotein. Note: p-values <0.05 indicates significant and from ANOVA model
C-peptide HOMA of Insulin Resistance:
There was an increase in insulin resistance after treatment with compound of formula (I). The percent change in HOMA IR from baseline following administration of compound of formula (1) 4 mg at Week 6 and Week 12 was statistically significant (27.87±4.22 and 58.29±5.74 respectively[p-value: 0.0001 each]) (Table 3).
Table 3: Analyses of change in HOMA of insulin resistance for C-Peptide from'baseline by visit
COMPOUND OF
FORMULA(I) 4 mg
Laboratory Test (Unit) Visit (N=49)
Homa of Insulin Resistance for Visit 1 n 49 C-Peptide
Mean ± SD 1.59 ± 0.82
- Median 1.40
Minimum 0.50
Maximum 3.80
Visit 3(Week 6) n 49
Mean ± SD 1.86 ± 0.77
Median 1.70
Minimum 0.90
Maximum 3.60 : Table 3: Analyses of change in HOMA of insulin resistance for C-Peptide from baseline by visit
COMPOUND OF
FORMULA(I) 4 mg
Laboratory Test (Unit) Visit (N=49)
Change from Visit I 0.27±0.05 (LS Mean ± SE)
p-values <0.0001
% Change from Visit 27.87±4.22
1 1
(LS Mean ± SE)
p-values <0.0001
Visit 4(Week n 49 12)
Mean ± SD 2.15 ± 0.62
Median 2.10
Minimum 1.10
Maximum 3.60
Change from Visit 1 0.56±0.05 (LS Mean ± SE)
p-values O.0001 .
% Change from Visit 58.29±5.74 1
(LS Mean ± SE)
p-values <0.0001
Key to abbreviations: HOMA: homeostasis model assessment, IR: insulin resistance, LSM = least square means; N = number of subjects in the treatment group; n = number of subjects having non-missing baseline and post-baseline values; SD = standard deviation; SE = standard error
Note: p-values <0.05 indicates significant and from ANOVA model
Insulin (fasting):
There was an increase in insulin resistance after treatment with compound of formula (I). The percent change in Insulin from baseline following administration of compound of formula (1) 4 mg at Week 6 and Week 12 was statistically significant (23.7 3.55 and 47.10±4.21 respectively [p-value: O.0001 each]) (Table 4).
Figure imgf000023_0001
Table 4: Analyses of Change in Insulin (fasting) from baseline by visit
COMPOUND OF FORMULA (I) 4 mg
Laboratory Test (Unit) Visit (N=49)
Key to abbreviations: LSM = least square means; N = number of subjects in the treatment group; n = number of subjects having non-missing baseline and post-baseline values; SD = standard deviation; SE = standard error
Note: p-values <0.05 indicates significant and from ANOVA model
Insulin HOMA of Beta-cell Function:
There was an increase in HOMA of Beta-cell function derived from Insulin after treatment with compound of formula (1). The percent change in the HOMA of Beta-cell function derived from Insulin from baseline at Week 6 and Week 12 was statistically significant (52.50±14.94 and 45.64±6.22, respectively [p-value: 0.0010 and <0.0001 , respectiveIy])(TabIe 5).
Table 5: Analyses of change in HOMA of Beta Cell Function for Insulin from baseline by visit
COMPOUND OF FORMULA(I) 4 mg
Laboratory Test (Unit) Visit (N=49)
HOMA of Beta Cell Function Visit 1 n 48 for Insulin
Mean ± SD 107.82 ± 52.85
Median 97.25
Minimum 10.20
Maximum 234.50
Visit 3(Week 6) n 49
Mean ± SD 136.41 ± 76.00
Median 1 16.50
Minimum 34.90
Maximum 348.00
Change from Visit 1 29.55±8.76 (LS Mean ± SE)
p-values 0.0015
% Change from Visit 1 52.50±14.94 (LS Mean ± SE) Table 5: Analyses of change in HOMA of Beta Cell Function for Insulin from baseline by visit
COMPOUND OF FORMULA(I) 4 mg
Laboratory Test (Unit) Visit (N=49)
p-values 0.0010
Visit 4(Week n 49
12)
Mean ± SD 137.56 ± 46.1 1
Median 125.60
Minimum 9.80
Maximum 273.30
Change from Visit 1 30.78±4.25 (LS Mean ± SE)
p-values <0.0001
% Change from Visit 1 45.64±6.22 (LS Mean ± SE)
p-values O.0001
Key to abbreviations: HOMA: homeostasis model assessment, LSM = least square means; N = number of subjects in the treatment group; n = number of subjects having non-missing baseline and post- baseline values; SD = standard deviation; SE = standard error Note: p-values <0.05 indicates significant and from ANOVA model
Efficacy Conclusions
Primary endpoint:
• There was a statistically significant reduction from baseline in serum TG levels at Week 6 and Week 12 following compound of formula (I) 4 mg (percent change of -40.98±4.89 and -45.1 1±3.60, respectively [p value: O.0001 , each])
Secondary Endpoints:
• There was no statistically significant change in the non-HDL cholesterol levels from baseline following administration of compound of formula (I) 4 mg at Week 6 and Week 12 (p-values: 0.3963 and 0.4646, respectively)
• There was a statistically significant increase in the HDL cholesterol levels from baseline following administration of compound of formula (1) 4 mg at Week 6 and Week 12 (percent change: 29.92±5.73 and 34.56±6.13, respectively [p- value: <0.0001 each]).
• There was a statistically significant increase in the HOMA of Beta-cell function derived from C-peptide from baseline following administration of compound of formula (I) 4 mg at Week 6 and Week 12 (68.25±25.58 and 71 .67±16.20, respectively [p-value: 0.0104 and O.0001 , respectively]).
• There was a statistically significant increase in the HOMA of insulin resistance derived from insulin from baseline after treatment with compound of formula (I) at Week 6 and Week 12 (percent change: 29.10±3.94 and 42.65±3.79, respectively [p-value: <0.0001 each]).
Therefore, the compound of the present invention including pharmaceutical compositions containing the same was found to be useful for the treatment of lipohypertrophy, lipoatrophy and Metabolic abnormalities in HIV patients.

Claims

We claim,
1. A method for the treatment of lipodystrophy which comprises administering a compound of formula (I)
Figure imgf000027_0001
(i)
wherein 'R' is selected from hydroxy, hydroxyalkyl, acyl, alkoxy, alkylthio, thioalkyl, aryloxy, arylthio and M+ represents suitable metal cations selected from Na+, K+, Ca+2, Mg+2 to a patient in need thereof.
2. The method as claimed in claim 1 , wherein 'R' represents thioalkyl, alkoxy or hydroxyalkyl group.
3. The method as claimed in claim 1 wherein 'R' represents -SCH3 or -OCH3 group.
4. The method as claimed in claim 1 wherein M+ represents Mg+2.
5. The method as claimed in claim 1 wherein the lipodystophy is HIV associated lipodystrophy.
6. The method as claimed in any one of the preceding claims wherein the HIV associated lipodystrophy causes lipohypertrophy or lipoatrophy or metabolic abnormality.
7. Use of the compound of formula (I) as claimed in any one of the preceding claims for the preparation of a medicament for the treatment of HIV associated lipodystrophy.
8. Use of the compound of formula (1) as claimed in any one of the preceding claims for the preparation of a medicament for the treatment of lipohypertrophy or lipoatrophy or metabolic abnormality.
9. Use of the compound of formula (1) as claimed in any one of the preceding claims wherein the compound is administrated in a daily dosage range selected from 1 mg to 500 mg given singly or in multiple divided dosage.
10. The daily dosage as claimed in claim 9 which is in the range of 4 mg to 250 mg given singly or in multiple divided dosage.
1 1. The daily dosage as claimed in claim 9 & 10 which is in the range of 4 mg to 50 mg.
12. The method of treatment or use of compound of formula (I) as claimed in preceding claims which is administrated in combination with other suitable therapeutic agent.
13. A pharmaceutical composition for the treatment of lipodystophy comprising a) The compound of formula (I) or its salt thereof as claimed in claim 1 ;
b) a suitable stabilizer;
c) a suitable buffering agent;
d) optionally, with one or more pharmaceutically acceptable excipients.
14. The pharmaceutical composition as claimed in claim 13 wherein the suitable stabilizer is selected from Polacrilin potassium, Potassium chloride and Sodium stearyl fumarate.
15. The pharmaceutical composition as claimed in claim 13 wherein the suitable stabilizer is preferably selected from Sodium stearyl fumarate.
16. The pharmaceutical composition as claimed in claim 13 wherein the suitable buffering agents are selected from Sodium acetate, Ammonia solution, Ammonium carbonate, Sodium borate, Adipic Acid, Glycine, monosodium glutamate.
17. The pharmaceutical composition as claimed in claim 16 wherein the suitable buffering agent is preferably selected from Ammonia solution.
18. The method for treating HIV associated lipodystrophy in a patient in need of such treatment comprising providing to such a patient the pharmaceutical composition as claimed in claim 13.
19. The method as claimed in claim 19 wherein the HIV associated lipodystrophy causes lipohypertrophy or lipoatrophy or metabolic abnormality.
20. Use of the pharmaceutical composition as claimed in any one of the preceding claims for the preparation of medicament for the treatment of HIV associated lipodystrophy.
21. Use of the pharmaceutical composition as claimedin any one of the preceding claims for the treatment of medicament for the treatment of lipohypertrophy or lipoatrophy or metabolic abnormality
22. The pharmaceutical composition as claimed in any one of the preceding claims in combination with another suitable agent selected from an agent used to control blood glucose levels, an agent used to control lipid levels, an agent used to lower or control cholesterol, an antioxidant, an appetite suppressing agent, an anti-obesity agent a probiotic or an anti-inflammatory agent.
23. The compound of formula (la)
Figure imgf000029_0001
(la)
wherein 'R' is selected from hydroxy, hydroxyalkyl, acyl, alkoxy, alkylthio, thioalkyl, aryloxy, arylthio and M+ represents suitable metal cations selected from K+, Mg+2.
24. The compound as claimed in claim 23, wherein 'R' represents thioalkyl, alkoxy or hydroxyalkyl group.
25. The compound as claimed in claim 23 wherein 'R' represents -SCH3 or -OCH3 group.
+ +2
26. The compound as claimed in claim 23 wherein M represents Mg .
27. The compound as claimed in claims 23-26 for the treatment lipodystrophy.
28. The compound as claimed in claim 27 wherein the lipodystrophy is HIV associated lipodystrophy.
29. The compound as claimed in any one of the preceding claims which reduces the concentration of triglyceride, Very low density lipoprotein, Apo B level.
30. The compound as claimed in any one of the preceding claims which increases high density lipoprotein, Apo A l level.
31. A pharmaceutical composition comprising compound of formula (la) for the treatment of lipodystrophy.
32. The pharmaceutical composition as claimed in claim 31 wherein the lipodystrophy is HIV associated lipodystrophy.
PCT/IN2012/000069 2011-01-31 2012-01-30 Treatment for lipodystrophy Ceased WO2012104869A1 (en)

Priority Applications (30)

Application Number Priority Date Filing Date Title
BR112013019352-2A BR112013019352A2 (en) 2011-01-31 2012-01-30 method for the treatment of lipodystrophy, use of a compound, daily dosage, treatment method, pharmaceutical composition, use of the pharmaceutical composition and compound
SI201230540A SI2670486T1 (en) 2011-01-31 2012-01-30 Treatment for lipodystrophy
UAA201309497A UA110813C2 (en) 2011-01-31 2012-01-30 Treatment of lipodystrophy
KR1020137021703A KR20130128451A (en) 2011-01-31 2012-01-30 Treatment for lipodystrophy
AU2012212992A AU2012212992B2 (en) 2011-01-31 2012-01-30 Treatment for lipodystrophy
KR1020157022081A KR101633720B1 (en) 2011-01-31 2012-01-30 Treatment for lipodystrophy
US13/978,791 US10017470B2 (en) 2011-01-31 2012-01-30 Treatment for lipodystrophy
MEP-2016-73A ME02392B (en) 2011-01-31 2012-01-30 TREATMENT OF LIPODYSTROPHY
EA201391108A EA025421B1 (en) 2011-01-31 2012-01-30 Treatment for lipodystrophy
MX2013008012A MX350611B (en) 2011-01-31 2012-01-30 Treatment for lipodystrophy.
SG2013050430A SG191772A1 (en) 2011-01-31 2012-01-30 Treatment for lipodystrophy
PH1/2013/501533A PH12013501533A1 (en) 2011-01-31 2012-01-30 Treatment for lipodystrophy
RS20160295A RS54735B1 (en) 2011-01-31 2012-01-30 LIPODYSTROPHY TREATMENT
HRP20160403TT HRP20160403T1 (en) 2011-01-31 2012-01-30 Treatment for lipodystrophy
NZ612804A NZ612804B2 (en) 2012-01-30 Treatment for lipodystrophy
JP2013551015A JP2014504610A (en) 2011-01-31 2012-01-30 Treatment of lipodystrophy
CN2012800067602A CN103354757A (en) 2011-01-31 2012-01-30 Treatment of lipodystrophy
MYPI2013701165A MY191100A (en) 2011-01-31 2012-01-30 Treatment for lipodystrophy
KR1020167007592A KR101733414B1 (en) 2011-01-31 2012-01-30 Treatment for lipodystrophy
EP12710562.5A EP2670486B1 (en) 2011-01-31 2012-01-30 Treatment for lipodystrophy
AP2013006988A AP3920A (en) 2011-01-31 2012-01-30 Treatment for lipodystrophy
CA2825456A CA2825456C (en) 2011-01-31 2012-01-30 Treatment for lipodystrophy
DK12710562.5T DK2670486T3 (en) 2011-01-31 2012-01-30 TREATMENT FOR LIPODYSTROPHY
PL12710562T PL2670486T3 (en) 2011-01-31 2012-01-30 Treatment for lipodystrophy
ES12710562.5T ES2569248T3 (en) 2011-01-31 2012-01-30 Treatment for lipodystrophy
IL22726613A IL227266B (en) 2011-01-31 2013-06-30 Treatment for lipodystrophy
SM201600129T SMT201600129B (en) 2011-01-31 2016-05-04 TREATMENT OF LIPODYSTROPHY
US15/345,035 US9783495B2 (en) 2011-01-31 2016-11-07 Treatment for lipodystrophy
US15/992,957 US20190100492A1 (en) 2011-01-31 2018-05-30 Treatment for lipodystrophy
IL262611A IL262611A (en) 2011-01-31 2018-10-25 Treatment for lipodystrophy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN257MU2011 2011-01-31
IN257/MUM/2011 2011-01-31

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US13/978,791 A-371-Of-International US10017470B2 (en) 2011-01-31 2012-01-30 Treatment for lipodystrophy
US15/345,035 Division US9783495B2 (en) 2011-01-31 2016-11-07 Treatment for lipodystrophy
US15/992,957 Continuation US20190100492A1 (en) 2011-01-31 2018-05-30 Treatment for lipodystrophy

Publications (1)

Publication Number Publication Date
WO2012104869A1 true WO2012104869A1 (en) 2012-08-09

Family

ID=54192841

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2012/000069 Ceased WO2012104869A1 (en) 2011-01-31 2012-01-30 Treatment for lipodystrophy

Country Status (29)

Country Link
US (3) US10017470B2 (en)
EP (2) EP2670486B1 (en)
JP (2) JP2014504610A (en)
KR (3) KR101733414B1 (en)
CN (2) CN103354757A (en)
AP (1) AP3920A (en)
AU (2) AU2012212992B2 (en)
BR (1) BR112013019352A2 (en)
CA (1) CA2825456C (en)
CL (1) CL2013002166A1 (en)
CO (1) CO6781497A2 (en)
CY (1) CY1117564T1 (en)
DK (1) DK2670486T3 (en)
EA (1) EA025421B1 (en)
ES (1) ES2569248T3 (en)
HR (1) HRP20160403T1 (en)
HU (1) HUE027512T2 (en)
IL (2) IL227266B (en)
ME (1) ME02392B (en)
MX (1) MX350611B (en)
MY (1) MY191100A (en)
PH (1) PH12013501533A1 (en)
PL (1) PL2670486T3 (en)
RS (1) RS54735B1 (en)
SG (1) SG191772A1 (en)
SI (1) SI2670486T1 (en)
SM (1) SMT201600129B (en)
UA (1) UA110813C2 (en)
WO (1) WO2012104869A1 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014195967A2 (en) 2013-05-30 2014-12-11 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
WO2015001573A1 (en) * 2013-07-05 2015-01-08 Cadila Healthcare Limited Synergistic compositions
WO2015011730A1 (en) * 2013-07-25 2015-01-29 Cadila Healthcare Limited Formulation comprising a hypolipidemic agent
WO2015029066A1 (en) 2013-08-29 2015-03-05 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
WO2015033357A2 (en) 2013-09-06 2015-03-12 Cadila Healthcare Limited An improved process for the preparation of pyrrole derivatives
EP2988736A1 (en) * 2013-04-22 2016-03-02 Cadila Healthcare Limited A novel composition for nonalcoholic fatty liver disease (nafld)
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
WO2017089979A1 (en) 2015-11-26 2017-06-01 Cadila Healthcare Limited Dual ppar modulators for the treatment of diabetic nephropathy and related diseases
WO2017089980A1 (en) 2015-11-26 2017-06-01 Cadila Healthcare Limited Dual ppar modulators for the treatment of diabetic retinopathy and diabetic eye diseases
US9783495B2 (en) 2011-01-31 2017-10-10 Cadila Healthcare Limited Treatment for lipodystrophy
WO2018104916A1 (en) 2016-12-09 2018-06-14 Cadila Healthcare Limited Treatment for primary biliary cholangitis
EP3270931A4 (en) * 2015-02-27 2018-10-03 Ionis Pharmaceuticals, Inc. Modulation of apolipoprotein c-iii (apociii) expression in lipodystrophy populations
WO2020128815A1 (en) 2018-12-18 2020-06-25 Cadila Healthcare Limited Saroglitazar for the treatment of hepatocellular carcinoma
US12201611B2 (en) 2020-07-24 2025-01-21 Zydus Lifesciences Limited Composition comprising high purity pyrrole derivative and method for preparation thereof
WO2025115040A1 (en) * 2023-12-01 2025-06-05 Zydus Lifesciences Limited Novel co-crystals of saroglitazar and saroglitazar mg salt
WO2025238663A1 (en) * 2024-05-16 2025-11-20 Zydus Lifesciences Limited Saroglitazar for the treatment of alcoholic liver diseases

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
JP6989262B2 (en) 2014-10-27 2022-01-05 アセコー インコーポレイテッド Subcutaneous outpatient management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
CA2993275C (en) 2015-08-20 2022-06-21 Aseko, Inc. Diabetes management therapy advisor

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991019702A1 (en) 1990-06-14 1991-12-26 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
WO1994001420A1 (en) 1992-07-03 1994-01-20 Smithkline Beecham Plc Heterocyclic compounds as pharmaceutical
WO1994013650A1 (en) 1992-12-04 1994-06-23 Smithkline Beecham Plc Heterocyclic derivatives and their use in pharmaceuticals
WO1995003038A1 (en) 1993-07-23 1995-02-02 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
WO1995017394A1 (en) 1993-12-22 1995-06-29 Smithkline Beecham Plc. Heterocyclic derivatives and their use in pharmaceuticals
WO1996004261A1 (en) 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
WO1996033998A1 (en) 1995-04-28 1996-10-31 Daiichi Pharmaceutical Co., Ltd. Pentacyclic compounds
WO1997025042A1 (en) 1996-01-09 1997-07-17 Smithkline Beecham P.L.C. Use of an agonist of ppar-alpha and ppar-gamma for the treatment of syndrom x
WO1997036579A1 (en) 1996-03-30 1997-10-09 Glaxo Group Limited Use of agonists of the peroxisome proliferator activated receptor alpha for treating obesity
WO1998028534A1 (en) 1996-12-24 1998-07-02 Daewoo Motor Co., Ltd. An apparatus of exhaust gas recirculation valve for an internal combustion engine
WO1999008501A2 (en) 1998-04-23 1999-02-25 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO1999016758A1 (en) 1997-10-27 1999-04-08 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
WO1999020614A1 (en) 1998-05-27 1999-04-29 Dr. Reddy's Research Foundation Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
WO2000023417A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
WO2000023445A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
WO2000023451A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
WO2001053257A2 (en) 2000-01-19 2001-07-26 Cadila Healthcare Ltd. Compounds having hypolipedemic and hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them
WO2003009841A1 (en) * 2001-07-26 2003-02-06 Cadila Healthcare Limited Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (en) 1980-06-06 1987-04-10 Sankyo Co A MICROBIOLOGICAL PROCEDURE FOR PREPARING DERIVATIVES OF ML-236B
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (en) 1989-07-21 1995-08-25 Warner Lambert Co Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts
CO5150173A1 (en) 1998-12-10 2002-04-29 Novartis Ag COMPOUNDS N- (REPLACED GLYCLE) -2-DIPEPTIDYL-IV PEPTIDASE INHIBITING CYANOPIRROLIDINS (DPP-IV) WHICH ARE EFFECTIVE IN THE TREATMENT OF CONDITIONS MEDIATED BY DPP-IV INHIBITION
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
AU2001286163A1 (en) 2000-09-22 2002-04-02 Dr. Reddy's Research Foundation An improved process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
JP4261546B2 (en) 2003-09-26 2009-04-30 三菱レイヨン株式会社 Electrophoresis apparatus and electrophoresis method
EA013427B1 (en) 2004-03-15 2010-04-30 Такеда Фармасьютикал Компани Лимитед DIPEPTIDYLPEPTIDASE INHIBITORS
US20090196923A1 (en) * 2006-04-26 2009-08-06 Jayanta Kumar Mandal Controlled release formulation comprising anti-epileptic drugs
AU2010323066B2 (en) 2009-11-26 2014-12-11 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
BR112013008985A2 (en) 2010-10-12 2016-07-05 Cerecor Inc antitussive compositions comprising memantine
EP2670486B1 (en) 2011-01-31 2016-04-06 Cadila Healthcare Limited Treatment for lipodystrophy
MY180160A (en) 2013-04-22 2020-11-23 Cadila Healthcare Ltd A novel composition for nonalcoholic fatty liver disease (nafld)
EP3004053B1 (en) 2013-05-30 2021-03-24 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201513857A (en) 2013-07-05 2015-04-16 Cadila Healthcare Ltd Synergistic compositions
IN2013MU02470A (en) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
US9951009B2 (en) 2013-08-29 2018-04-24 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
IN2013MU02905A (en) 2013-09-06 2015-07-03 Cadila Healthcare Ltd

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991019702A1 (en) 1990-06-14 1991-12-26 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
WO1994001420A1 (en) 1992-07-03 1994-01-20 Smithkline Beecham Plc Heterocyclic compounds as pharmaceutical
WO1994013650A1 (en) 1992-12-04 1994-06-23 Smithkline Beecham Plc Heterocyclic derivatives and their use in pharmaceuticals
WO1995003038A1 (en) 1993-07-23 1995-02-02 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
WO1995017394A1 (en) 1993-12-22 1995-06-29 Smithkline Beecham Plc. Heterocyclic derivatives and their use in pharmaceuticals
WO1996004261A1 (en) 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
WO1996004260A1 (en) 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pyridine derivatives useful in the treatment of the type ii diabetes
WO1996033998A1 (en) 1995-04-28 1996-10-31 Daiichi Pharmaceutical Co., Ltd. Pentacyclic compounds
WO1997025042A1 (en) 1996-01-09 1997-07-17 Smithkline Beecham P.L.C. Use of an agonist of ppar-alpha and ppar-gamma for the treatment of syndrom x
WO1997036579A1 (en) 1996-03-30 1997-10-09 Glaxo Group Limited Use of agonists of the peroxisome proliferator activated receptor alpha for treating obesity
WO1998028534A1 (en) 1996-12-24 1998-07-02 Daewoo Motor Co., Ltd. An apparatus of exhaust gas recirculation valve for an internal combustion engine
WO1999016758A1 (en) 1997-10-27 1999-04-08 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
WO1999008501A2 (en) 1998-04-23 1999-02-25 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO1999020614A1 (en) 1998-05-27 1999-04-29 Dr. Reddy's Research Foundation Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
WO2000023417A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
WO2000023445A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
WO2000023451A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
WO2001053257A2 (en) 2000-01-19 2001-07-26 Cadila Healthcare Ltd. Compounds having hypolipedemic and hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them
WO2003009841A1 (en) * 2001-07-26 2003-02-06 Cadila Healthcare Limited Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BHASIN ET AL., J CLIN ENDOCRINOL METAB, 2007
HULGAN ET AL., J INFECT DIS, 2008
MALLON ET AL., J INFECT DIS, 2005
PATHOGENESIS AND TREATMENT OF LIPODYSTROPHY, vol. I 6, no. 4, October 2004 (2004-10-01)

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9783495B2 (en) 2011-01-31 2017-10-10 Cadila Healthcare Limited Treatment for lipodystrophy
US10017470B2 (en) 2011-01-31 2018-07-10 Cadila Healthcare Limited Treatment for lipodystrophy
JP2016515608A (en) * 2013-04-22 2016-05-30 カディラ・ヘルスケア・リミテッド Novel composition for non-alcoholic fatty liver disease (NAFLD)
US9814697B2 (en) 2013-04-22 2017-11-14 Cadila Healthcare Limited Composition for nonalcoholic fatty liver disease (NAFLD)
EP2988736A1 (en) * 2013-04-22 2016-03-02 Cadila Healthcare Limited A novel composition for nonalcoholic fatty liver disease (nafld)
US20160166539A1 (en) * 2013-04-22 2016-06-16 Cadila Healthcare Limited A novel composition for nonalcoholic fatty liver disease (nafld)
US10435363B2 (en) 2013-05-30 2019-10-08 Cadila Healthcare Limited Process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
WO2014195967A3 (en) * 2013-05-30 2015-03-26 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
WO2014195967A2 (en) 2013-05-30 2014-12-11 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
US20160107989A1 (en) * 2013-05-30 2016-04-21 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
JP2016523824A (en) * 2013-07-05 2016-08-12 カディラ ヘルスケア リミティド Synergistic composition
US9656954B2 (en) 2013-07-05 2017-05-23 Cadila Healthcare Limited Synergistic compositions
US10315993B2 (en) 2013-07-05 2019-06-11 Cadila Healthcare Limited Synergistic compositions
WO2015001573A1 (en) * 2013-07-05 2015-01-08 Cadila Healthcare Limited Synergistic compositions
US9957230B2 (en) * 2013-07-05 2018-05-01 Cadila Healthcare Limited Synergistic compositions
US20170320823A1 (en) * 2013-07-05 2017-11-09 Cadila Healthcare Limited Synergistic compositions
EP3120845A1 (en) * 2013-07-05 2017-01-25 Cadila Healthcare Limited Synergistic compositions
AU2014285704B2 (en) * 2013-07-05 2017-02-23 Cadila Healthcare Limited Synergistic compositions
JP2017105780A (en) * 2013-07-05 2017-06-15 カディラ ヘルスケア リミティド Synergistic composition
JP2016523895A (en) * 2013-07-25 2016-08-12 カディラ ヘルスケア リミティド Formulations containing lipid lowering agents
US10098868B2 (en) 2013-07-25 2018-10-16 Cadila Healthcare Limited Formula comprising a hypolipidemic agent
US9610277B2 (en) 2013-07-25 2017-04-04 Cadila Healthcare Limited Formula comprising a hypolipidemic agent
AU2014294548B2 (en) * 2013-07-25 2017-08-10 Cadila Healthcare Limited Formulation comprising a hypolipidemic agent
WO2015011730A1 (en) * 2013-07-25 2015-01-29 Cadila Healthcare Limited Formulation comprising a hypolipidemic agent
KR101786843B1 (en) * 2013-07-25 2017-10-18 카딜라 핼쓰캐어 리미티드 Formulation comprising a hypolipidemic agent
CN105407873A (en) * 2013-07-25 2016-03-16 卡迪拉保健有限公司 Formulation comprising hypolipidemic agent
US20180297945A1 (en) * 2013-08-29 2018-10-18 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
WO2015029066A1 (en) 2013-08-29 2015-03-05 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
US20160207884A1 (en) * 2013-08-29 2016-07-21 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
US9951009B2 (en) 2013-08-29 2018-04-24 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
US20160194280A1 (en) * 2013-09-06 2016-07-07 Cadila Healthcare Limited Improved process for the preparation of pyrrole derivatives
US10112898B2 (en) 2013-09-06 2018-10-30 Cadila Healthcare Limited Process for the preparation of saroglitazar pharmaceutical salts
WO2015033357A2 (en) 2013-09-06 2015-03-12 Cadila Healthcare Limited An improved process for the preparation of pyrrole derivatives
WO2015033357A3 (en) * 2013-09-06 2015-05-07 Cadila Healthcare Limited An improved process for the preparation of pyrrole derivatives
EP3270931A4 (en) * 2015-02-27 2018-10-03 Ionis Pharmaceuticals, Inc. Modulation of apolipoprotein c-iii (apociii) expression in lipodystrophy populations
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
US10385017B2 (en) 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
WO2017089979A1 (en) 2015-11-26 2017-06-01 Cadila Healthcare Limited Dual ppar modulators for the treatment of diabetic nephropathy and related diseases
WO2017089980A1 (en) 2015-11-26 2017-06-01 Cadila Healthcare Limited Dual ppar modulators for the treatment of diabetic retinopathy and diabetic eye diseases
WO2018104916A1 (en) 2016-12-09 2018-06-14 Cadila Healthcare Limited Treatment for primary biliary cholangitis
US11433050B2 (en) 2016-12-09 2022-09-06 Cadila Healthcare Ltd. Treatment for primary biliary cholangitis
US11872209B2 (en) 2016-12-09 2024-01-16 Zydus Lifesciences Limited Treatment for primary biliary cholangitis
US12178799B2 (en) 2016-12-09 2024-12-31 Zydus Lifesciences Limited Treatment for primary biliary cholangitis
WO2020128815A1 (en) 2018-12-18 2020-06-25 Cadila Healthcare Limited Saroglitazar for the treatment of hepatocellular carcinoma
US12201609B2 (en) 2018-12-18 2025-01-21 Zydus Lifesciences Limited Saroglitazar for the treatment of hepatocellular carcinoma
US12201611B2 (en) 2020-07-24 2025-01-21 Zydus Lifesciences Limited Composition comprising high purity pyrrole derivative and method for preparation thereof
WO2025115040A1 (en) * 2023-12-01 2025-06-05 Zydus Lifesciences Limited Novel co-crystals of saroglitazar and saroglitazar mg salt
WO2025238663A1 (en) * 2024-05-16 2025-11-20 Zydus Lifesciences Limited Saroglitazar for the treatment of alcoholic liver diseases

Also Published As

Publication number Publication date
KR20150100949A (en) 2015-09-02
PH12013501533A1 (en) 2013-09-16
CO6781497A2 (en) 2013-10-31
ES2569248T3 (en) 2016-05-09
UA110813C2 (en) 2016-02-25
IL227266A0 (en) 2013-09-30
CA2825456C (en) 2016-01-05
EP2670486B1 (en) 2016-04-06
EP2670486A1 (en) 2013-12-11
EA025421B1 (en) 2016-12-30
SI2670486T1 (en) 2016-09-30
US9783495B2 (en) 2017-10-10
HRP20160403T1 (en) 2016-06-03
JP5956664B2 (en) 2016-07-27
AU2012212992B2 (en) 2015-11-26
US20130338209A1 (en) 2013-12-19
MY191100A (en) 2022-05-30
HUE027512T2 (en) 2016-10-28
PL2670486T3 (en) 2016-08-31
IL227266B (en) 2019-10-31
EA201391108A1 (en) 2013-12-30
CL2013002166A1 (en) 2014-04-11
AP3920A (en) 2016-12-02
SG191772A1 (en) 2013-08-30
US20170088514A1 (en) 2017-03-30
CA2825456A1 (en) 2012-08-09
US20190100492A1 (en) 2019-04-04
AU2012212992A1 (en) 2013-07-25
CN107056671A (en) 2017-08-18
MX2013008012A (en) 2013-08-21
AU2015249076A1 (en) 2015-11-12
AP2013006988A0 (en) 2013-07-31
JP2016028069A (en) 2016-02-25
NZ612804A (en) 2015-09-25
KR20160038073A (en) 2016-04-06
JP2014504610A (en) 2014-02-24
BR112013019352A2 (en) 2020-07-14
ME02392B (en) 2016-09-20
CY1117564T1 (en) 2017-04-26
US10017470B2 (en) 2018-07-10
RS54735B1 (en) 2016-10-31
DK2670486T3 (en) 2016-05-17
EP3009136A1 (en) 2016-04-20
CN103354757A (en) 2013-10-16
KR101633720B1 (en) 2016-06-27
KR101733414B1 (en) 2017-05-10
IL262611A (en) 2018-12-31
SMT201600129B (en) 2016-07-01
KR20130128451A (en) 2013-11-26
MX350611B (en) 2017-09-11

Similar Documents

Publication Publication Date Title
US9783495B2 (en) Treatment for lipodystrophy
US11459311B2 (en) Pharmaceutical composition containing indirubin derivative as active ingredient
US20250152614A1 (en) Compositions And Methods For Inducing Apoptosis In Anaerobic Cells And Related Clinical Methods For Treating Cancer And Pathogenic Infections
RU2655811C2 (en) Therapeutic agent for amyotrophic lateral sclerosis
AU2015268725B2 (en) Treatment for lipodystrophy
EP2862573B1 (en) Composition for treating or preventing diseases caused by vascular permeability, containing imatinib or pharmaceutically acceptable salt thereof as active ingredient
RU2653478C2 (en) Method of improvement of liver function
NZ612804B2 (en) Treatment for lipodystrophy
HK1243065A (en) Treatment for lipodystrophy
HK1243065A1 (en) Treatment for lipodystrophy
HK1188964A (en) Treatment for lipodystrophy
CN116887822A (en) How to treat achondroplasia
KR20230059075A (en) Pharmaceutical composition for preventing or treating diabetes comprising quinizarin
HK40097164A (en) Activation effect of agilawood component on ampk

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12710562

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2013551015

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/008012

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2012710562

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2825456

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2012212992

Country of ref document: AU

Date of ref document: 20120130

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13177319

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2013002166

Country of ref document: CL

WWE Wipo information: entry into national phase

Ref document number: A201309497

Country of ref document: UA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1301004230

Country of ref document: TH

ENP Entry into the national phase

Ref document number: 20137021703

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: DZP2013000522

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 201391108

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 13978791

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013019352

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: P-2016/0295

Country of ref document: RS

ENP Entry into the national phase

Ref document number: 112013019352

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130730